Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate a positive sentiment. The company's strategic plan shows strong product development with NDA approval and commercial launch goals. The Q&A reveals confidence in manufacturing and IP, though some details remain vague. The partnership with Adare Pharma Solutions and the AI-driven commercial platform are promising. Despite some uncertainties, the overall outlook is optimistic, with a potential market opportunity and supportive clinical data. The sentiment is positive, with a likely stock price increase in the short term.
Key Financial Performance
Transformational Financing $180 million in upfront capital, plus up to $174 million from milestone-based warrants. This financing was supported by a syndicate of leading specialist healthcare investors.
Operational Progress First cytisinicline engineering batch produced at Adare Pharma Solutions' facility. This partnership is expected to decrease risks related to international importation of pharmaceuticals, including potential tariffs.
Scientific Data Advancement Phase III participants demonstrated consistent efficacy regardless of prior treatment history. Among participants with prior varenicline and bupropion use, those receiving 12 weeks of cytisinicline achieved continuous abstinence rates of 32.4% versus 6% on placebo with an odds ratio of 7.5.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Treatment Development: Achieve Life Sciences is developing a new treatment for smoking and vaping cessation, addressing a significant unmet need as there has not been a new FDA-approved smoking cessation therapy in over two decades.
Scientific Data Advancement: Published mechanistic data showing cytisinicline's selective interaction with the alpha 4 beta 2 nicotinic receptor and minimal interaction with the 5-HT3 serotonin receptor, explaining its tolerability. Clinical trials demonstrated significant efficacy, especially in difficult-to-treat populations.
Commercial Launch Preparation: Achieve plans to commercially launch cytisinicline in the first half of 2027, with readiness efforts underway.
Manufacturing Partnership: Partnered with Adare Pharma Solutions to manufacture cytisinicline domestically, reducing risks related to international importation and tariffs. Produced the first engineering batch in Q1 2026.
Financing: Secured $180 million in upfront capital and up to $174 million in milestone-based warrants from leading healthcare investors, positioning the company for success.
Leadership and Board Expansion: Appointed new Board members and commercial team leaders with extensive experience in successful pharmaceutical launches, enhancing the company's strategic capabilities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company expects to receive a complete response letter from the FDA due to a third-party manufacturer receiving an official action indicated classification. This could delay the approval and launch of their product.
Supply Chain Risks: The company is transitioning to a new manufacturing partner, Adare Pharma Solutions, to mitigate risks related to international importation and tariffs. However, this transition and reliance on a new partner could pose operational risks.
Commercial Launch Timeline: The expected commercial launch of the product has been delayed to the first half of 2027, which could impact revenue generation and market positioning.
Market Competition: The company is entering a market with no new FDA-approved smoking cessation therapies in over two decades, but faces the challenge of addressing unmet needs and competing with existing therapies.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Commercial Launch Timeline: The company plans to resubmit the NDA in the fourth quarter of 2026, naming Adare Pharma Solutions as the new and primary manufacturing partner for commercial supply. The expected commercial launch is in the first half of 2027.
Manufacturing Strategy: Achieve has partnered with U.S.-based Adare Pharma Solutions to manufacture cytisinicline drug product for potential commercial supply. This partnership aims to mitigate risks related to international importation of pharmaceuticals, including potential tariffs.
Scientific Advancements: The company presented data showing cytisinicline's selective interaction with the alpha 4 beta 2 nicotinic receptor and minimal interaction with the 5-HT3 serotonin receptor, potentially explaining its tolerability. Phase III trial results demonstrated significant efficacy in difficult-to-treat populations, with continuous abstinence rates of 32.4% versus 6% on placebo.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the commercial strategy and what needs to be achieved in 2026 for the launch?
A:The company plans to commercialize independently with its own field force. They are building a data-driven strategy and have recruited a strong leadership team. Specifics will be shared as decisions firm up.
Q:What is the awareness level among current CHANTIX prescribers about cytisinicline and Phase III data?
A:The company is constrained in pre-approval communication but shares clinical data through scientific channels. They plan to present new data at conferences and expand their medical education team closer to approval and launch.
Q:What additional information is needed for the NDA resubmission, and how is Adare progressing in manufacturing?
A:The focus is on transitioning manufacturing to Adare due to issues with a prior third-party manufacturer. The company has already produced initial batches and is working on completing the tech transfer to Adare as quickly as possible.
Q:What due diligence was done on the IP for cytisinicline, and how confident are you in the manufacturing timeline?
A:Extensive due diligence was conducted on the IP, and the company is confident in its durability into the late 2030s and 2040s. They are evaluating timelines and have not seen any issues that would prevent meeting them.
Q:How are you addressing the evolving dynamics in the vaping market and the priority voucher for vaping?
A:The company is not dependent on the priority voucher but sees it as an indication of FDA alignment with public health needs. They plan to initiate the vaping Phase III trial this year and will update timelines as they finalize the design.
Q:Will the company focus on a wider approach at launch and invest in patient support programs?
A:The company plans a broader commercial strategy and emphasizes equipping prescribers with effective therapy. They foresee offering patient support programs leveraging digital and tele-infrastructure.
Q:Will there be additional clinical work before refiling the NDA?
A:The focus is on getting the drug approved through the completed clinical program and ramping up the vaping study. Additional studies may be considered for specific subsets of the smoking community.
Q:What is the timeline for the CNPV and the size of the field team for commercial expectations?
A:The company plans to initiate the ORCA-V2 trial as soon as possible and will scale the field force in alignment with the opportunity, starting with a reasonable size and expanding as needed.
Q:Will the NDA resubmission be Class I or Class II, and what is the status of the European manufacturer?
A:The company is waiting for information from the FDA to determine the resubmission class. They have severed ties with the European manufacturer and replaced them with a U.S. partner.
Q:Does the emergence of new smoking cessation aids affect the messaging for cytisinicline?
A:The company views the increased attention to smoking cessation as helpful and is confident in the unique profile of cytisinicline, which is easy to take and has strong efficacy and tolerability.
Q:Will the relationship with Omnicom change with the new team?
A:The company is evaluating all partners to align with its strategy and will choose the best ones for its current and future needs.
Q:Will the drug batches for the ORCA-V trial be manufactured by Adare, and is the readiness of the facility key to starting the trial?
A:The company has the ability to generate clinical trial supply and has already ramped up manufacturing with Adare. They are working on sourcing the trial with appropriate supply.
Q:What is driving the decision to push the NDA resubmission to Q4?
A:The decision is based on completing the technology transfer and analytical method transfer accurately and meeting all necessary milestones.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the size of the field force, the exact specifications of the priority voucher timeline, and whether the NDA resubmission would be Class I or Class II. Additionally, they did not commit to specific numbers or timelines for certain aspects of the commercial strategy and manufacturing readiness.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Communications Stakeholder
Dr Chief
Dr QA
Instructions reminder
Officer remark
Officer replay
President Strategic
QA Chief
Relations statement
Relations today
Sciences Conference
Sciences Dr
Sciences website
Stakeholder Relations
Strategic Communications
Vice President
Webcast Instructions
conference Vice
factor Dr
factor Vice
release Life
remark Dr
result filing
ACHV Transcript
Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call summary and Q&A indicate a positive sentiment. The company's strategic plan shows strong product development with NDA approval and commercial launch goals. The Q&A reveals confidence in manufacturing and IP, though some details remain vague. The partnership with Adare Pharma Solutions and the AI-driven commercial platform are promising. Despite some uncertainties, the overall outlook is optimistic, with a potential market opportunity and supportive clinical data. The sentiment is positive, with a likely stock price increase in the short term.
Achieve Life Sciences, Inc. (ACHV) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call reveals significant concerns: a net loss of $54.7 million, limited cash reserves, and ongoing economic and financial risks. The Q&A section highlights unproven commercial execution strategies and unclear timelines for manufacturing and regulatory approvals. While there is optimism for future product launches, the lack of finalized pricing strategies and potential supply chain issues further contribute to a negative outlook. These factors outweigh any positive aspects, suggesting a likely stock price decline in the short term.
Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents a mixed picture. While there are positive aspects such as the preparation for commercial launch and favorable safety outcomes, there are significant risks including regulatory approval, financial constraints, and competitive pressures. The Q&A section highlights uncertainties, particularly regarding the vaping study and funding, which could weigh on investor sentiment. Given the absence of immediate catalysts and the potential for delays, the overall stock reaction is likely to remain neutral.
Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call summary presents a mixed outlook. The company is on track with NDA submission and has positive clinical trial results, but faces financial challenges with a significant cash burn and net loss. The Q&A section reveals cautious optimism about pricing strategy and partnerships, but lacks clarity in some areas. The focus on cash management and the absence of priority review expectations temper the outlook. Overall, the sentiment is neutral, reflecting both potential positives and ongoing uncertainties.
ACHV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
